studies

metastatic/advanced - colorectal cancer (mCRC), atezolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsAtezoTRIBE, 2022 0.66 [0.36; 1.19] IMblaze-370 (A ; all population), 2019 1.00 [0.73; 1.37] IMblaze-370 (AC ; all population), 2019 1.00 [0.73; 1.37] MODUL, 2023 0.98 [0.64; 1.50] 0.95[0.79; 1.15]AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019, MODUL, 202340%1,116moderatenot evaluable deaths (OS) (extension)detailed resultsMODUL, 2023 0.83 [0.65; 1.05] 0.83[0.65; 1.05]MODUL, 202310%445NAnot evaluable PFS (extension)detailed resultsMODUL, 2023 0.95 [0.77; 1.18] 0.95[0.77; 1.18]MODUL, 202310%445NAnot evaluable progression or deaths (PFS)detailed resultsAtezoTRIBE, 2022 0.69 [0.56; 0.85] IMblaze-370 (A ; all population), 2019 1.39 [1.00; 1.94] IMblaze-370 (AC ; all population), 2019 1.25 [0.94; 1.66] MODUL, 2023 0.92 [0.72; 1.17] 1.01[0.73; 1.39]AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019, MODUL, 2023483%1,116moderatenot evaluable objective responses (ORR)detailed resultsAtezoTRIBE, 2022 0.78 [0.53; 1.14] IMblaze-370 (A ; all population), 2019 1.00 [0.14; 7.26] IMblaze-370 (AC ; all population), 2019 1.24 [0.24; 6.50] 0.80[0.56; 1.16]AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201930%671moderatenot evaluable objective responses (ORR) (extension)detailed resultsAtezoTRIBE, 2022 0.77 [0.44; 1.36] 0.77[0.44; 1.36]AtezoTRIBE, 202210%218NAnot evaluable AE (any grade)detailed resultsIMblaze-370 (A ; all population), 2019 0.62 [0.18; 2.22] IMblaze-370 (AC ; all population), 2019 1.52 [0.42; 5.53] MODUL, 2023 2.49 [1.25; 4.95] 1.52[0.68; 3.43]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019, MODUL, 2023344%865moderatenot evaluable AE (grade 3-4)detailed resultsAtezoTRIBE, 2022 1.29 [0.71; 2.32] IMblaze-370 (A ; all population), 2019 0.33 [0.18; 0.63] IMblaze-370 (AC ; all population), 2019 1.15 [0.67; 1.97] 0.80[0.35; 1.80]AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019383%643moderatenot evaluable AE (grade 3-5)detailed resultsMODUL, 2023 1.40 [0.91; 2.15] 1.40[0.91; 2.15]MODUL, 202310%436NAnot evaluable AE leading to death (grade 5)detailed resultsAtezoTRIBE, 2022 2.03 [0.09; 45.56] IMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90] IMblaze-370 (AC ; all population), 2019 1.12 [0.21; 5.90] 0.93[0.25; 3.49]AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201930%647moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsAtezoTRIBE, 2022 3.09 [0.15; 62.46] IMblaze-370 (A ; all population), 2019 0.49 [0.14; 1.72] IMblaze-370 (AC ; all population), 2019 2.72 [1.15; 6.39] 1.43[0.38; 5.40]AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019360%643moderatenot evaluable SAE (any grade)detailed resultsAtezoTRIBE, 2022 1.06 [0.56; 2.00] IMblaze-370 (A ; all population), 2019 0.69 [0.32; 1.48] IMblaze-370 (AC ; all population), 2019 2.26 [1.24; 4.14] 1.22[0.61; 2.41]AtezoTRIBE, 2022, IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019368%643moderatenot evaluable STRAE (any grade)detailed resultsIMblaze-370 (A ; all population), 2019 0.67 [0.24; 1.88] IMblaze-370 (AC ; all population), 2019 2.73 [1.26; 5.89] 1.41[0.35; 5.60]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019278%429moderatenot evaluable TRAE (any grade)detailed resultsIMblaze-370 (A ; all population), 2019 0.05 [0.01; 0.16] IMblaze-370 (AC ; all population), 2019 0.74 [0.19; 2.79] 0.18[0.01; 2.73]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019289%429moderatenot evaluable TRAE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.12 [0.05; 0.26] IMblaze-370 (AC ; all population), 2019 0.85 [0.50; 1.44] 0.32[0.05; 2.26]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019294%429moderatenot evaluable TRAE leading to death (grade 5)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] IMblaze-370 (AC ; all population), 2019 0.89 [0.08; 9.99] 0.71[0.10; 5.06]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.08; 9.99] 0.89[0.08; 9.99]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.05; 14.43] IMblaze-370 (AC ; all population), 2019 1.81 [0.20; 16.42] 1.37[0.24; 7.75]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 3.61 [0.16; 81.33] IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 1.61[0.14; 18.49]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 1.19 [0.26; 5.50] IMblaze-370 (AC ; all population), 2019 0.29 [0.05; 1.77] 0.64[0.16; 2.54]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019227%429moderatenot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.63[0.04; 10.13]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Anaemia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90] IMblaze-370 (AC ; all population), 2019 2.31 [0.49; 10.78] 1.06[0.12; 9.33]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019244%429moderatenot evaluable Arthralgia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.31[0.03; 3.47]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Asthenia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 1.80 [0.16; 20.18] IMblaze-370 (AC ; all population), 2019 3.22 [0.39; 26.58] 2.50[0.51; 12.27]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Back pain AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 5.48 [0.27; 111.16] IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 2.17[0.20; 23.63]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Colitis AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 1.79 [0.06; 53.98] IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.79[0.18; 17.83]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Constipation AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.07; 11.69]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Cough AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.63[0.04; 10.13]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90] IMblaze-370 (AC ; all population), 2019 0.44 [0.06; 3.19] 0.36[0.07; 1.91]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Dermatitis acneiform AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.37[0.12; 15.71]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.17 [0.02; 1.47] IMblaze-370 (AC ; all population), 2019 1.89 [0.68; 5.22] 0.69[0.07; 7.10]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019274%429moderatenot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.07; 11.69]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Dysphonia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.63[0.04; 10.13]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.61 [0.19; 2.02] IMblaze-370 (AC ; all population), 2019 0.49 [0.17; 1.40] 0.54[0.25; 1.19]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Guillain-Barré syndrome AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.07; 11.69]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Headache AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.07; 11.69]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Hypertension AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.24 [0.06; 0.91] IMblaze-370 (AC ; all population), 2019 0.08 [0.02; 0.37] 0.15[0.05; 0.44]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 2019213%429moderatenot evaluable Increased ALT AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.31[0.03; 3.47]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.37[0.12; 15.71]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Intestinal perforation AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.31[0.03; 3.47]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.37[0.12; 15.71]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Myalgia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.31[0.03; 3.47]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Nausea AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.37[0.12; 15.71]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.04 [0.00; 0.77] IMblaze-370 (AC ; all population), 2019 0.02 [0.00; 0.39] 0.03[0.00; 0.24]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.31[0.03; 3.47]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.37[0.12; 15.71]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Pneumonitis AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 1.79 [0.06; 53.98] IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 1.26[0.11; 14.04]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Pruritus AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.63[0.04; 10.13]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Pyrexia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 6.47 [0.36; 115.44] 3.23[0.32; 33.03]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Rash AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.04; 4.93] IMblaze-370 (AC ; all population), 2019 1.59 [0.32; 7.82] 1.08[0.28; 4.07]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Rash maculopapular AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] IMblaze-370 (AC ; all population), 2019 0.44 [0.03; 7.19] 0.44[0.05; 3.83]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Sepsis AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90] IMblaze-370 (AC ; all population), 2019 0.44 [0.06; 3.19] 0.36[0.07; 1.91]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Stomatitis AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.63[0.04; 10.13]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.07; 11.69]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Vomiting AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.07; 11.69]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable Weight decreased AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.63[0.04; 10.13]IMblaze-370 (A ; all population), 2019, IMblaze-370 (AC ; all population), 201920%429moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-09-28 03:10 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 183,384,137,138 - treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons